Find Skin Cancer Clinical Trials near You

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Beaumont Hospital-Dearborn

from

Dearborn, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Cancer Care Specialists of Illinois - Decatur

from

Decatur, IL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Trinity Regional Medical Center

from

Fort Dodge, IA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Wheaton Franciscan Healthcare-Franklin

from

Franklin, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Palo Alto Medical Foundation-Fremont

from

Fremont, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Central Care Cancer Center - Garden City

from

Garden City, KS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Tidelands Georgetown Memorial Hospital

from

Georgetown, SC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Aurora Health Care Germantown Health Center

from

Germantown, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Central Care Cancer Center - Great Bend

from

Great Bend, KS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Hawaii Cancer Care Inc-POB II

from

Honolulu, HI

Novant Health Presbyterian Medical Center Huntersville

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Huntersville, NC

Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Jonesboro, AR

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Northwell Health- Center for Advanced Medicine

from

Lake Success, NY

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Sechler Family Cancer Center

from

Lebanon, PA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Hope Cancer Clinic

from

Livonia, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Joseph London

from

London, KY

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Centra Lynchburg Hematology Oncology Clinic

from

Lynchburg, VA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Aurora Bay Area Medical Group-Marinette

from

Marinette, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Thompson Oncology Group-Maryville

from

Maryville, TN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

UH Seidman Cancer Center at Landerbrook Health Center

from

Mayfield Heights, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Sloan Kettering Monmouth

from

Middletown, NJ

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Monticello Cancer Center

from

Monticello, MN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Chancellor Center for Oncology

from

Newburgh, IN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ascension Providence Hospitals - Novi

from

Novi, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Nebraska Cancer Specialists - Omaha

from

Omaha, NE

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Alphonsus Medical Center-Ontario

from

Ontario, OR

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Hope Cancer Care of Nevada-Pahrump

from

Pahrump, NV

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Lake Huron Medical Center

from

Port Huron, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Beaufort Memorial Keyserling Cancer Center

from

Port Royal, SC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ascension Saint Mary's Hospital

from

Rhinelander, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Riverton Hospital

from

Riverton, UT

Great Lakes Cancer Management Specialists-Rochester Hills

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Rochester Hills, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Siteman Cancer Center at Christian Hospital

from

Saint Louis, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mercy Hospital South

from

Saint Louis, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser San Rafael-Gallinas

from

San Rafael, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Essentia Health Sandstone

from

Sandstone, MN

UH Seidman Cancer Center at Firelands Regional Medical Center

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Sandusky, OH

MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Sanford, ME

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

HSHS Saint Nicholas Hospital

from

Sheboygan, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Marshfield Clinic Stevens Point Center

from

Stevens Point, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ascension Saint Michael's Hospital

from

Stevens Point, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Novant Health Oncology Specialists-Davidson County

from

Thomasville, NC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Macomb Hematology Oncology PC

from

Warren, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Joseph Warren Hospital

from

Warren, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

UPMC Susquehanna

from

Williamsport, PA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Abington Memorial Hospital-Asplundh Cancer Pavilion

from

Willow Grove, PA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Elizabeth Youngstown Hospital

from

Youngstown, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

IHA Hematology Oncology Consultants-Ann Arbor

from

Ypsilanti, MI

University of South Florida- H. Lee Moffitt Cancer Center and Research Institute

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Genesis Healthcare System Cancer Care Center

from

Zanesville, OH

Melanoma Clinical Trial

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)

Status: Enrolling, Phase III
Updated: 8/10/2016

Merck Sharp & Dohme

from

North Ryde,

Metastatic Melanoma Clinical Trial

innovaTIL-01, Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Tampa, FL

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Status: Enrolling, Phase I, II
Updated: 12/31/1969

Univ. of Okalhoma Health Sciences Center

from

Oklahoma City, OK

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Status: Enrolling, Phase I, II
Updated: 12/31/1969

Stanford Hospitals and Clinics

from

Palo Alto, CA

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Status: Enrolling, Phase II
Updated: 12/31/1969

Border Medical Oncology Research Unit

from

Albury,

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Status: Enrolling, Phase II
Updated: 12/31/1969

University Cancer & Blood Center, LLC; Research

from

Athens, GA

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Status: Enrolling, Phase II
Updated: 12/31/1969

Wheaton Franciscan Cancer Care-All Saints

from

Franklin, WI

Immunology / Infectious Diseases, Oncology Clinical Trial

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Status: Enrolling, Phase II
Updated: 12/31/1969

Midwestern Regional Medical Center

from

Zion, IL

Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms

Status: Enrolling, Phase I
Updated: 12/31/1969

Zuckerberg San Francisco General Hospital

from

San Francisco, CA

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Status: Enrolling, Phase I, II
Updated: 12/31/1969

from

Philadelphia, PA

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Status: Enrolling, Phase I, II
Updated: 12/31/1969

from

Saint Louis, MO

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Status: Enrolling, Phase II
Updated: 12/31/1969

Chevy Chase RCCA

from

Chevy Chase, MD

Non-melanoma Skin Cancer Clinical Trial

Topical Chemoprevention of Skin Cancer Biomarkers

Status: Enrolling
Updated: 12/31/1969

University of Alabama at Birmingham Whitaker Clinic

from

Birmingham, AL

Melanoma, Ocular Clinical Trial

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Status: Enrolling, Phase III
Updated: 12/31/1969

Universitätsklinikum Graz

from

Graz,

Melanoma, Ocular Clinical Trial

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Status: Enrolling, Phase III
Updated: 12/31/1969

Atlantic Melanoma Center at Morristown Medical Center

from

Morristown, NJ

A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

Status: Enrolling, Phase I, II
Updated: 12/31/1969

Research Facility

from

Cleveland, OH

Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Status: Enrolling, Phase I, II
Updated: 12/31/1969

The Kinghorn Cancer Centre

from

Darlinghurst,

Registry Study for Talimogene Laherparepvec

Status: Enrolling, Phase
Updated: 12/31/1969

Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial

from

Aurora, CO

Registry Study for Talimogene Laherparepvec

Status: Enrolling, Phase
Updated: 12/31/1969

Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial

from

Canton, OH

Registry Study for Talimogene Laherparepvec

Status: Enrolling, Phase
Updated: 12/31/1969

Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial

from

Miami Beach, FL

Registry Study for Talimogene Laherparepvec

Status: Enrolling, Phase
Updated: 12/31/1969

Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial

from

Minneapolis, MN

Registry Study for Talimogene Laherparepvec

Status: Enrolling, Phase
Updated: 12/31/1969

Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial Clinical Trial

from

Morristown, NJ

Registry Study for Talimogene Laherparepvec

Status: Enrolling, Phase
Updated: 12/31/1969

from

Park Ridge, IL

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Alphonsus Medical Center-Baker City

from

Baker City, OR

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

Farmington Health Center

from

Farmington, UT

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

OhioHealth Mansfield Hospital

from

Mansfield, OH

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

Delbert Day Cancer Institute at PCRMC

from

Rolla, MO

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

Summit Cancer Care-Candler

from

Savannah, GA

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

South Jordan Health Center

from

South Jordan, UT

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

Promedica Flower Hospital

from

Sylvania, OH

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

McFarland Clinic PC - Ames

from

Ames, IA

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Duluth Clinic Ashland

from

Ashland, WI

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Central Care Cancer Center - Bolivar

from

Bolivar, MO

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

IHA Hematology Oncology Consultants-Brighton

from

Brighton, MI

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Alphonsus Cancer Care Center-Caldwell

from

Caldwell, ID

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Hematology Oncology Consultants-Clarkston

from

Clarkston, MI

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Essentia Health - Deer River Clinic

from

Deer River, MN

University of Florida Health Science Center ?? Gainesville

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Gainesville, FL

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Vincent Hospital Cancer Center Green Bay

from

Green Bay, WI

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Yale-New Haven Shoreline Medical Center

from

Guilford, CT

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Essentia Health Hibbing Clinic

from

Hibbing, MN

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Hawaii Oncology Inc-POB I

from

Honolulu, HI

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Essentia Health - Jamestown Clinic

from

Jamestown, ND

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Good Samaritan Medical Center

from

Lafayette, CO

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Desert West Surgery

from

Las Vegas, NV

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Hope Cancer Care of Nevada

from

Las Vegas, NV

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Comprehensive Cancer Centers of Nevada - Town Center

from

Las Vegas, NV

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Michigan Breast Specialists-Macomb Township

from

Macomb, MI

Great Lakes Cancer Management Specialists-Macomb Medical Campus

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Macomb, MI

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Fairview Maple Grove Medical Center

from

Maple Grove, MN